Impetigo - Pipeline Review, H2 2020
Impetigo - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Pipeline Review, H2 2020, provides an overview of the Impetigo (Infectious Disease) pipeline landscape.
Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, having diabetes and having a compromised immune system. Treatment includes antibiotics.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Impetigo - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Impetigo (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Impetigo (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Unknown stages are 1, 1, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Impetigo (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Pipeline Review, H2 2020, provides an overview of the Impetigo (Infectious Disease) pipeline landscape.
Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, having diabetes and having a compromised immune system. Treatment includes antibiotics.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Impetigo - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Impetigo (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Impetigo (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Unknown stages are 1, 1, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Impetigo (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Impetigo (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Impetigo (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Impetigo (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Impetigo (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Impetigo (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Impetigo (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Impetigo (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Impetigo - Overview
Impetigo - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Impetigo - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Impetigo - Companies Involved in Therapeutics Development
FUJIFILM Toyama Chemical Co Ltd
Laboratories Ojer Pharma SL
Next Science Ltd
Union Therapeutics AS
Vaxcyte Inc
Impetigo - Drug Profiles
Drug for Impetigo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mupirocin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niclosamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ozenoxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme to Disrupt Bacterial Cell Wall for Impetigo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAX-24 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Impetigo - Dormant Projects
Impetigo - Discontinued Products
Impetigo - Product Development Milestones
Featured News & Press Releases
Mar 05, 2018: Newly Approved Treatment for Impetigo to be Commercialized by Cutanea Life Sciences
Jan 08, 2018: Cipher Pharmaceuticals Announces Canadian Launch of OZANEX (ozenoxacin cream 1%), a Novel Topical Antibiotic
Dec 14, 2017: Medimetriks Pharmaceuticals Receives FDA Approval for Xepi (ozenoxacin) Cream, 1%, a Novel Topical Antibiotic for Impetigo
May 08, 2017: Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX (ozenoxacin cream 1%)
Jul 12, 2016: Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada
Jun 27, 2016: Medimetriks Pharmaceuticals New Drug Application for Ozenoxacin Cream, 1% Accepted for Review by FDA
Jun 27, 2016: Medimetriks Pharmaceuticals Submits a New Drug Application to FDA for Ozenoxacin Cream, 1%, a Novel Impetigo Treatment
Jun 12, 2014: Medimetriks Pharmaceuticals Announces that the Second Phase III Study for Ozenoxacin has been Initiated by Ferrer
Jun 05, 2013: Ferrer Completes Phase III Clinical Trial Of Ozenoxacin In Adult And Pediatric Patients With Impetigo
Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles As Young As Two Months Of Age For New Antibacterial Compound Ozenoxacin
Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical Treatment For Impetigo And Other Infectious Dermatological Conditions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Impetigo - Overview
Impetigo - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Impetigo - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Impetigo - Companies Involved in Therapeutics Development
FUJIFILM Toyama Chemical Co Ltd
Laboratories Ojer Pharma SL
Next Science Ltd
Union Therapeutics AS
Vaxcyte Inc
Impetigo - Drug Profiles
Drug for Impetigo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mupirocin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niclosamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ozenoxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme to Disrupt Bacterial Cell Wall for Impetigo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAX-24 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Impetigo - Dormant Projects
Impetigo - Discontinued Products
Impetigo - Product Development Milestones
Featured News & Press Releases
Mar 05, 2018: Newly Approved Treatment for Impetigo to be Commercialized by Cutanea Life Sciences
Jan 08, 2018: Cipher Pharmaceuticals Announces Canadian Launch of OZANEX (ozenoxacin cream 1%), a Novel Topical Antibiotic
Dec 14, 2017: Medimetriks Pharmaceuticals Receives FDA Approval for Xepi (ozenoxacin) Cream, 1%, a Novel Topical Antibiotic for Impetigo
May 08, 2017: Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX (ozenoxacin cream 1%)
Jul 12, 2016: Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada
Jun 27, 2016: Medimetriks Pharmaceuticals New Drug Application for Ozenoxacin Cream, 1% Accepted for Review by FDA
Jun 27, 2016: Medimetriks Pharmaceuticals Submits a New Drug Application to FDA for Ozenoxacin Cream, 1%, a Novel Impetigo Treatment
Jun 12, 2014: Medimetriks Pharmaceuticals Announces that the Second Phase III Study for Ozenoxacin has been Initiated by Ferrer
Jun 05, 2013: Ferrer Completes Phase III Clinical Trial Of Ozenoxacin In Adult And Pediatric Patients With Impetigo
Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles As Young As Two Months Of Age For New Antibacterial Compound Ozenoxacin
Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical Treatment For Impetigo And Other Infectious Dermatological Conditions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Impetigo, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Impetigo - Pipeline by FUJIFILM Toyama Chemical Co Ltd, H2 2020
Impetigo - Pipeline by Laboratories Ojer Pharma SL, H2 2020
Impetigo - Pipeline by Next Science Ltd, H2 2020
Impetigo - Pipeline by Union Therapeutics AS, H2 2020
Impetigo - Pipeline by Vaxcyte Inc, H2 2020
Impetigo - Dormant Projects, H2 2020
Impetigo - Discontinued Products, H2 2020
Number of Products under Development for Impetigo, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Impetigo - Pipeline by FUJIFILM Toyama Chemical Co Ltd, H2 2020
Impetigo - Pipeline by Laboratories Ojer Pharma SL, H2 2020
Impetigo - Pipeline by Next Science Ltd, H2 2020
Impetigo - Pipeline by Union Therapeutics AS, H2 2020
Impetigo - Pipeline by Vaxcyte Inc, H2 2020
Impetigo - Dormant Projects, H2 2020
Impetigo - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Impetigo, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
Number of Products under Development for Impetigo, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
